Press Releases

2008	Topic
30 July	Starts Phase IIa Trial of Potential First Drug Therapy for Cocaine Dependence
24 July	US Department of Defense Funds Trial Using Novel Compound from Synosia Therapeutics
10 June	Starts Proof-of-Mechanism Trial for Nitisinone in Parkinson's Disease
3 June	Begins Phase IIa Trial for Potential First-in-Class Treatment for Parkinson's Disease
31 March	Announces Start of Ph II Efficacy Trial for Rufinamide SYN-111
4 February	Appoints Chief Financial Officer to New Company Headquarters in Switzerland
22 January	Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug Rufinamide

Media inquiries

Julie Walters
Tudor Reilly (Europe)
Tel: +44 (0) 1494 753990
Fax: +44 (0) 1494 753991
Mobile: +44 (0) 775 3626967
Email: julie.walters@tudor-reilly.com

Michele Parisi
Tudor Reilly (US)
Tel: +1 925 864 5028
Email: michele.parisi@tudor-reilly.com